The Role of KL-6 in the Clinical Diagnosis of ILD
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
- Serums from patients with ILD: before treatment and 30-90 days after treatment
- Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
- Serums from patients with ILD: before treatment and 30-90 days after treatment
Exclusion Criteria
- Serums with visible precipitate
- Serums from patients with cancer
- Serums with floc
- Serums with visible precipitate
- Serums from patients with cancer
- Serums with floc
Summary
- Conditions
- Interstitial Lung Disease
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Retrospective
Participation Requirements
- Age
- Between 14 years and 90 years
- Gender
- Both males and females
Description
As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them...
As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and healthy control group. Part 2: The purpose of this part is to study the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and 30-90 days after treatment. Treatment includes anti fibrosis, anti-inflammatory and other conventional therapies.
Inclusion Criteria
- Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
- Serums from patients with ILD: before treatment and 30-90 days after treatment
- Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
- Serums from patients with ILD: before treatment and 30-90 days after treatment
Exclusion Criteria
- Serums with visible precipitate
- Serums from patients with cancer
- Serums with floc
- Serums with visible precipitate
- Serums from patients with cancer
- Serums with floc
Tracking Information
- NCT #
- NCT02197364
- Collaborators
- Fujirebio Diagnostics, Inc.
- Investigators
- Principal Investigator: Li Hui Ping Shanghai Pulmonary Hospital , Tongji University
- Li Hui Ping Shanghai Pulmonary Hospital , Tongji University
Get Well Soon